Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

医学 多西紫杉醇 内科学 培美曲塞 催眠药 肺癌 危险系数 肿瘤科 彭布罗利珠单抗 吉西他滨 无进展生存期 化疗 癌症 免疫疗法 置信区间 顺铂
作者
Karen L. Reckamp,Mary W. Redman,Konstantin H. Dragnev,Katherine Minichiello,Liza C. Villaruz,Bryan A. Faller,Tareq Al Baghdadi,Susan J. Hines,Leah Everhart,Louise Highleyman,Vassiliki A. Papadimitrakopoulou,Joel W. Neal,Saiama N. Waqar,Jyoti D. Patel,Jhanelle E. Gray,David R. Gandara,Karen Kelly,Roy S. Herbst
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:40 (21): 2295-2307 被引量:225
标识
DOI:10.1200/jco.22.00912
摘要

PURPOSE Resistance to immune checkpoint inhibition (ICI) in advanced non–small-cell lung cancer (NSCLC) represents a major unmet need. Combining ICI with vascular endothelial growth factor (VEGF)/VEGF receptor inhibition has yielded promising results in multiple tumor types. METHODS In this randomized phase II Lung-MAP nonmatch substudy (S1800A), patients ineligible for a biomarker-matched substudy with NSCLC previously treated with ICI and platinum-based chemotherapy and progressive disease at least 84 days after initiation of ICI were randomly assigned to receive ramucirumab plus pembrolizumab (RP) or investigator's choice standard of care (SOC: docetaxel/ramucirumab, docetaxel, gemcitabine, and pemetrexed). With a goal of 130 eligible patients, the primary objective was to compare overall survival (OS) using a one-sided 10% level using the better of a standard log-rank (SLR) and weighted log-rank (WLR; G[rho = 0, gamma = 1]) test. Secondary end points included objective response, duration of response, investigator-assessed progression-free survival, and toxicity. RESULTS Of 166 patients enrolled, 136 were eligible (69 RP; 67 SOC). OS was significantly improved with RP (hazard ratio [80% CI]: 0.69 [0.51 to 0.92]; SLR one-sided P = .05; WLR one-sided P = .15). The median (80% CI) OS was 14.5 (13.9 to 16.1) months for RP and 11.6 (9.9 to 13.0) months for SOC. OS benefit for RP was seen in most subgroups. Investigator-assessed progression-free survival (hazard ratio [80% CI]: 0.86 [0.66 to 1.14]; one-sided SLR, P = .25 and .14 for WLR) and response rates (22% RP v 28% SOC, one-sided P = .19) were similar between arms. Grade ≥ 3 treatment-related adverse events occurred in 42% of patients in the RP group and 60% on SOC. CONCLUSION This randomized phase II trial demonstrated significantly improved OS with RP compared with SOC in patients with advanced NSCLC previously treated with ICI and chemotherapy. The safety was consistent with known toxicities of both drugs. These data warrant further evaluation.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
Hello的应助被着急的焦采纳,获得10
刚刚
刚刚
yoyo20012623完成签到,获得积分10
1秒前
BAEKHYUNLUCKY发布了新的文献求助10
1秒前
木头木子发布了新的文献求助30
1秒前
3秒前
赘婿的应助被sdl采纳,获得10
3秒前
ColinWine完成签到,获得积分0
4秒前
安吉拉学术记完成签到,获得积分10
4秒前
Juvenilesy的应助被可乐斯汀采纳,获得10
5秒前
5秒前
Orange的应助被轻松夏槐采纳,获得10
5秒前
5秒前
6秒前
蜗牛完成签到,获得积分10
6秒前
7秒前
7秒前
7秒前
凤凰完成签到,获得积分10
8秒前
荼蘼发布了新的文献求助10
9秒前
万能图书馆的应助被时衍采纳,获得10
9秒前
石s完成签到,获得积分10
9秒前
9秒前
一条小鱼完成签到 ,获得积分10
9秒前
烟花的应助被三月采纳,获得10
10秒前
洋子发布了新的文献求助10
10秒前
山复尔尔发布了新的文献求助10
10秒前
情怀的应助被努力的xl采纳,获得10
10秒前
10秒前
11完成签到,获得积分10
11秒前
11秒前
11秒前
11秒前
仿生人发布了新的文献求助10
12秒前
调皮的问丝完成签到,获得积分10
12秒前
扶桑发布了新的文献求助10
12秒前
晨烨完成签到,获得积分10
13秒前
13秒前
破烂收藏家完成签到,获得积分10
13秒前
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175262
求助须知:如何正确求助?哪些是违规求助? 9567017
关于积分的说明 21789663
捐赠科研通 7769695
什么是DOI,文献DOI怎么找? 3431840
关于科研通互助平台的介绍 2556124
邀请新用户注册赠送积分活动 2477241